IVR治疗mCNV患者黄斑中心凹下脉络膜厚度分析

目的 观察玻璃体腔内注射雷珠单抗(IVR)治疗病理性近视脉络膜新生血管(mCNV)的有效性与安全性,同时观察患者黄斑中心凹下脉络膜厚度变化.方法 回顾性病例系列研究.将2014年11月至2018年12月诊断为初发活动期mCNV并接受IVR的38例42眼纳入研究.所有患者采取IVR 1针初始治疗联合按需注射(1+PRN)...

Subfoveal choroidal thickness changes following intravitreal ranibizumab treatment in choroidal neovascularization due to pathological myopia

Objective To observe the safety and effectiveness of intravitreal injection of ranizumab(IVR)on choroidal neovascularization due to pathological myopia(mCNV), and the changes of subfoveal choroidal thickness. Methods Retrospective case series study. 42 eyes of 38 patients from November 2014 to December 2018 with treatment-naïve active mCNV treatment by IVR were enrolled in the study. All patients were divided into single treatment group and retreatment group according to the injection numbers of IVR. The differences of best corrected visual acuity and subfoveal central choroidal thickness were observed. Results In the repeated treatment group, the injection numbers were 3.77±1.21. The baseline choroidal thickness of the single treatment group was(59.15±10.57)μm, and that of the retreatment group was(49.33±12.76)μm(P=0.023), in which central choroidal thickness(CCT)before retreatment increased to(55.22±7.63)μm(P=0.131). Conclusion 1+PRN regimen of IVR can effectively treat choroidal neovascularization due to pathological myopia. CCT may be a prognostic factor for retreatment.